Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
|Podcasts|February 27, 2010
Is ‘Maintenance Therapy’ in Metastatic Breast Cancer a Misnomer?
Author(s)Debu Tripathy, MD
Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference.
Advertisement
Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference sheds light on his presentation, The Role of Maintenance Therapy for Metastatic Breast Cancer, truly a complicated and controversial topic.
-Interviewed by Ron Piana
Advertisement
Related to this article
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5